GPMed welcomes the EU Biotech Act as an important step toward strengthening Europe’s position in global life sciences. The proposed framework aims to reduce regulatory barriers, accelerate innovation, and improve the translation of scientific discoveries into real-world healthcare solutions. For Austria and the wider EU, the Act represents a timely opportunity to create a more competitive, efficient, and innovation-friendly environment for clinical research and biotechnology.

Daten aus der klinischen Routine (Real-World Data, RWD) können evidenzbasierte Informationen (Real-World Evidence, RWE) für Forschung und Entwicklung sowie für politische und regulatorische Entscheidungen im gesamten Spektrum der Gesundheitsversorgung liefern